[Aldosterone exacerbates chronic renal insufficiency].
It is now clear that the synthesis of aldosterone (A) and the expression of the mineralocorticoid receptor also appear in the extra-adrenal tissues. Experimental studies have succeeded in showing the connection between A and the pathological mechanisms that appear in the development of chronic kidney diseases (CKD). Unfortunately, it is not currently possible to decide whether the effects of A are clinically relevant or not due to the lack of controlled trials.


CONCLUSIONS
A very likely has a role in the development of CKD, although considerably more clinical investigation is needed.
Afdeling P, Nefrologisk Klinik, Rigshospitalet, Denmark. kekristensen@hotmail.com
Karl Emil
KE
Kristensen
Martin
M
Egfjord
D000450:Aldosterone / Q000096:biosynthesis / Q000097:blood / Q000502:physiology*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D003928:Diabetic Nephropathies / Q000209:etiology / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D018161:Receptors, Mineralocorticoid / Q000378:metabolism; D051436:Renal Insufficiency, Chronic / Q000209:etiology / Q000378:metabolism* / Q000473:pathology / Q000517:prevention & control; D012307:Risk Factors; D013148:Spironolactone / Q000627:therapeutic use
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D018161:Receptors, Mineralocorticoid; D013148:Spironolactone; D000450:Aldosterone